RaySearch Laboratories AB (publ) (RAY_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Research Presentation of the First Quarter 2022. My name is Karolina Stavlis, and I'm Head of Investor Relations. As usual, our CEO and founder, Johan Löf, and our CFO, Nina Grönberg, will walk you through the key highlights and financial results of the quarter. After the presentation, we will open the floor for questions. Simply raise your hand in teams to ask a question live. And with that short introduction, I will now hand over to you, Johan. Thank you, Carolina, and welcome again, everyone. I apologize for my voice. I have a cold, as you can tell. Before we dive into the results and highlights, let me start with a quick overview of Razor's business. So Razor is a software company, and we focus on, and recommend. What we see here is a schematic view of a comprehensive cancer center. Although research has been focused on radiation therapy for the first 25 years, we are now about to expand into the other areas of cancer therapy, into chemotherapy, surgery, and liver ablation, for example. So everything that goes on in a comprehensive cancer I think it's important to look at the long-term performance on research. This diagram shows the revenue all the way back from 2008. And you can see here that there's been a steady growth every year. growing year over year. I would also like to show another view of the same thing, basically, where we also look for every year at the revenues for the individual quarters. And as you can see, for many of these years, there are fluctuations between quarters. We can look at 2017 for examples. It fluctuates, but nevertheless, there is a growth for the full 12 months. Another example can be 2022. You see fluctuations. Some of the weak issue too, but when you take all the quarters together, again, growth. 2024, the same thing. ...